General Information of the Drug (ID: M6APDG00239)
Name
Bis(5-aminobenzo[b]furan-2-yl)methanone
Synonyms
CHEMBL376787; bis(5-aminobenzo[b]furan-2-yl)methanone
    Click to Show/Hide
Status
Investigative
Structure
Formula
C17H12N2O3
InChI
1S/C17H12N2O3/c18-11-1-3-13-9(5-11)7-15(21-13)17(20)16-8-10-6-12(19)2-4-14(10)22-16/h1-8H,18-19H2
InChIKey
UMBJVNBINWLZLH-UHFFFAOYSA-N
PubChem CID
11098310
TTD Drug ID
D07AXL
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Platelet-derived growth factor receptor beta (PDGFRB)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
Response Summary Platelet-derived growth factor receptor beta (PDGFRB) is a therapeutic target for Bis(5-aminobenzo[b]furan-2-yl)methanone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Bis(5-aminobenzo[b]furan-2-yl)methanone through regulating the expression of Platelet-derived growth factor receptor beta (PDGFRB). [1], [2]
References
Ref 1 Mutant NPM1-Regulated FTO-Mediated m(6)A Demethylation Promotes Leukemic Cell Survival via PDGFRB/ERK Signaling Axis. Front Oncol. 2022 Feb 8;12:817584. doi: 10.3389/fonc.2022.817584. eCollection 2022.
Ref 2 Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97. doi: 10.1016/j.bmc.2006.12.011. Epub 2006 Dec 12.